International Assets Investment Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm purchased 5,061,530 shares of the biopharmaceutical company’s stock, valued at approximately $146,481,000. International Assets Investment Management LLC owned approximately 0.09% of Pfizer as of its most recent filing with the SEC.
A number of other institutional investors have also modified their holdings of the company. Marshall Wace LLP boosted its stake in Pfizer by 279.3% in the 2nd quarter. Marshall Wace LLP now owns 5,378,173 shares of the biopharmaceutical company’s stock worth $150,481,000 after purchasing an additional 8,378,173 shares in the last quarter. Swedbank AB acquired a new stake in Pfizer in the 1st quarter worth approximately $172,902,000. Pzena Investment Management LLC boosted its stake in Pfizer by 181.6% in the 1st quarter. Pzena Investment Management LLC now owns 7,670,445 shares of the biopharmaceutical company’s stock worth $212,855,000 after purchasing an additional 4,947,000 shares in the last quarter. Van ECK Associates Corp boosted its stake in Pfizer by 21.8% in the 1st quarter. Van ECK Associates Corp now owns 15,813,328 shares of the biopharmaceutical company’s stock worth $438,820,000 after purchasing an additional 2,829,178 shares in the last quarter. Finally, 1832 Asset Management L.P. boosted its stake in Pfizer by 24,961.6% in the 2nd quarter. 1832 Asset Management L.P. now owns 2,497,886 shares of the biopharmaceutical company’s stock worth $69,891,000 after purchasing an additional 2,487,919 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors.
Pfizer Trading Down 0.6 %
PFE stock opened at $28.46 on Friday. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54. The stock has a market cap of $161.27 billion, a price-to-earnings ratio of -61.96, a PEG ratio of 1.01 and a beta of 0.67. The business’s 50-day moving average is $29.07 and its 200 day moving average is $28.49.
Pfizer Announces Dividend
The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a yield of 5.90%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is -365.21%.
Wall Street Analyst Weigh In
Several analysts have commented on PFE shares. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Wednesday. Daiwa Capital Markets raised Pfizer from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Barclays increased their price target on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Citigroup started coverage on Pfizer in a research report on Friday. They set a “neutral” rating and a $30.00 price target on the stock. Eight investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus target price of $33.58.
View Our Latest Stock Report on Pfizer
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Further Reading
- Five stocks we like better than Pfizer
- Are Penny Stocks a Good Fit for Your Portfolio?
- Texas Roadhouse Stock Steering for New Highs This Year
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- Ride Out The Recession With These Dividend Kings
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.